Biotech Values

[woofer]

What do you think accounts for the fact that patients who took telaprevir for double the time- 24 weeks, had a smaller percentage of reported Grade 3 rash (4%) than those who were on telaprevir for only 12 weeks (6%)? The reason I point this out is because statistics can be misleading, especially with so few people involved.

Grade 3 rash was observed in 7 (6%), 5 (4%), 6 (5%) and 1 (1%) patients in T12/PR24, T24/PR48, T24/P24, and PR48, respectively.